Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622140 · ClinicalTrials.gov registry record
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
A clinical trial of Tuberculosis and Latent Tuberculosis Infection, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- 21,334
- Enrollment target
- 10
- Study locations
NCT01622140 is a study of Tuberculosis and Latent Tuberculosis Infection that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 21,334 participants, above the 199-participant average among 29 other Tuberculosis trials with a reported enrollment target (10621% higher). The trial reports 10 study locations across 10 states.
The verdict
NCT01622140, a study of Tuberculosis and Latent Tuberculosis Infection, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- 21,334 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tuberculosis infection (tuberculin skin test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) and will examine the rates of positive results among the cohort. This study will also determine the risk and rate of progression to active TB disease, overall and by the results of the three tests.
Conditions Studied
Study Locations (10)
Arizona
- Maricopa County Department of Public Health - Phoenix
California
- California Department of Public Health - Richmond
Colorado
- Denver Health and Hospitals Authority - Denver
Florida
- University of Florida Board of Trustees - Gainesville
Georgia
- Emory University - Atlanta
Hawaii
- Hawaii Department of Health - Honolulu
Maryland
- Maryland Department of Public Health - Baltimore
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,334 participants |
| Start Date | 2012-10 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01622140
The ClinicalTrials.gov registry entry for NCT01622140 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21,334 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 199-participant average among 29 other Tuberculosis trials with a reported enrollment target (10621% higher). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Tuberculosis appearing as the primary indexed condition, and to 0 interventions.
NCT01622140 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01622140 about?
NCT01622140 is a clinical study titled "Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis". This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tub...
What is the current status of trial NCT01622140?
This trial is currently completed. The enrollment target is 21,334 participants. The study started on 2012-10. Estimated completion is 2020-12-31.
What conditions does trial NCT01622140 study?
This clinical trial studies the following conditions: Tuberculosis, Latent Tuberculosis Infection.
Who is sponsoring clinical trial NCT01622140?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01622140 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.